CD8A and neoplasm: Recent studies have shown that gemcitabine can be transformed from being a non-ICD-mediated chemotherapeutic agent to an ICD-mediated chemotherapeutic agent through the COX-2/PGE2 pathway, which mediates a large number of CD8+ T cells into tumor tissues and enhances the anticancer efficacy of gemcitabine (184).